Literature DB >> 28096309

Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN.

Maria Chiara Marinozzi1,2, Lubka T Roumenina1,3,4, Sophie Chauvet1, Alexandre Hertig5, Dominique Bertrand6, Jérome Olagne7, Marie Frimat8, Tim Ulinski9, Georges Deschênes10, Stephane Burtey11, Michel Delahousse12, Bruno Moulin7, Christophe Legendre13, Véronique Frémeaux-Bacchi14,2, Moglie Le Quintrec14,12.   

Abstract

In C3 glomerulopathy (C3G), the alternative pathway of complement is frequently overactivated by autoantibodies that stabilize the C3 convertase C3bBb. Anti-C3b and anti-factor B (anti-FB) IgG have been reported in three patients with C3G. We screened a cohort of 141 patients with C3G and Ig-associated membranoproliferative GN (Ig-MPGN) for anti-FB and anti-C3b autoantibodies using ELISA. We identified seven patients with anti-FB IgG, three patients with anti-C3b IgG, and five patients with anti-FB and anti-C3b IgG. Of these 15 patients, ten were diagnosed with Ig-MPGN. Among those patients with available data, 92% had a nephrotic syndrome, 64% had AKI, and 67% had a documented infection. Patients negative for anti-C3b and anti-FB IgG had much lower rates of infection (17 [25%] patients with C3G and one [10%] patient with Ig-MPGN). After 48 months, four of 15 (26%) positive patients had developed ESRD or died. All 15 patients had high plasma Bb levels, six (40%) patients had low levels of C3, and nine (60%) patients had high levels of soluble C5b9. In vitro, IgG purified from patients with anti-FB Abs selectively enhanced C3 convertase activity; IgG from patients with anti-C3b/anti-FB Abs enhanced C3 and C5 cleavage. IgG from patients with anti-C3b Abs stabilized C3bBb and perturbed C3b binding to complement receptor 1 but did not perturb binding to factor H. In conclusion, the prevalence of anti-C3b/anti-FB Abs and alternative pathway activation is similar in Ig-MPGN and C3G, suggesting similar pathogenic mechanisms. Identification of the underlying defect in Ig-MPGN could lead to improved treatment.
Copyright © 2017 by the American Society of Nephrology.

Entities:  

Keywords:  chronic glomerulonephritis; clinical immunology; complement

Mesh:

Substances:

Year:  2017        PMID: 28096309      PMCID: PMC5407719          DOI: 10.1681/ASN.2016030343

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  24 in total

Review 1.  Membranoproliferative glomerulonephritis--a new look at an old entity.

Authors:  Sanjeev Sethi; Fernando C Fervenza
Journal:  N Engl J Med       Date:  2012-03-22       Impact factor: 91.245

Review 2.  Alternative complement pathway assessment in patients with atypical HUS.

Authors:  Lubka T Roumenina; Chantal Loirat; Marie-Agnes Dragon-Durey; Lise Halbwachs-Mecarelli; Catherine Sautes-Fridman; Veronique Fremeaux-Bacchi
Journal:  J Immunol Methods       Date:  2011-01-06       Impact factor: 2.303

Review 3.  Basic and translational concepts of immune-mediated glomerular diseases.

Authors:  William G Couser
Journal:  J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 10.121

Review 4.  The role of complement in C3 glomerulopathy.

Authors:  Peter F Zipfel; Christine Skerka; Qian Chen; Thorsten Wiech; Tim Goodship; Sally Johnson; Veronique Fremeaux-Bacchi; Clara Nester; Santiago Rodríguez de Córdoba; Marina Noris; Matthew Pickering; Richard Smith
Journal:  Mol Immunol       Date:  2015-04-28       Impact factor: 4.407

5.  Eculizumab for treatment of rapidly progressive C3 glomerulopathy.

Authors:  Moglie Le Quintrec; Arnaud Lionet; Christine Kandel; Franck Bourdon; Viviane Gnemmi; Magali Colombat; Jean-Michel Goujon; Véronique Frémeaux-Bacchi; Fadi Fakhouri
Journal:  Am J Kidney Dis       Date:  2014-12-17       Impact factor: 8.860

6.  Heterogeneous pattern of renal disease associated with homozygous factor H deficiency.

Authors:  Aude Servais; Laure-Hélène Noël; Marie-Agnes Dragon-Durey; Marie-Claire Gübler; Philippe Rémy; David Buob; Carole Cordonnier; Raïfah Makdassi; Waddah Jaber; Eric Boulanger; Philippe Lesavre; Véronique Frémeaux-Bacchi
Journal:  Hum Pathol       Date:  2011-03-10       Impact factor: 3.466

7.  Effectiveness of mycophenolate mofetil in C3 glomerulonephritis.

Authors:  Cristina Rabasco; Teresa Cavero; Elena Román; Jorge Rojas-Rivera; Teresa Olea; Mario Espinosa; Virginia Cabello; Gema Fernández-Juarez; Fayna González; Ana Ávila; José María Baltar; Montserrat Díaz; Raquel Alegre; Sandra Elías; Monserrat Antón; Miguel Angel Frutos; Alfonso Pobes; Miguel Blasco; Francisco Martín; Carmen Bernis; Manuel Macías; Sergio Barroso; Alberto de Lorenzo; Gema Ariceta; Manuel López-Mendoza; Begoña Rivas; Katia López-Revuelta; José María Campistol; Santiago Mendizábal; Santiago Rodríguez de Córdoba; Manuel Praga
Journal:  Kidney Int       Date:  2015-07-29       Impact factor: 10.612

8.  Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis.

Authors:  Vasil V Vasilev; Remi Noe; Marie-Agnes Dragon-Durey; Sophie Chauvet; Valentin J Lazarov; Boriana P Deliyska; Veronique Fremeaux-Bacchi; Jordan D Dimitrov; Lubka T Roumenina
Journal:  J Biol Chem       Date:  2015-08-05       Impact factor: 5.157

9.  Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.

Authors:  Paraskevas Iatropoulos; Marina Noris; Caterina Mele; Rossella Piras; Elisabetta Valoti; Elena Bresin; Manuela Curreri; Elena Mondo; Anna Zito; Sara Gamba; Serena Bettoni; Luisa Murer; Veronique Fremeaux-Bacchi; Marina Vivarelli; Francesco Emma; Erica Daina; Giuseppe Remuzzi
Journal:  Mol Immunol       Date:  2016-02-16       Impact factor: 4.407

10.  Novel factor H mutation associated with familial membranoproliferative glomerulonephritis type I.

Authors:  Hadas Alfandary; Miriam Davidovits
Journal:  Pediatr Nephrol       Date:  2015-08-20       Impact factor: 3.714

View more
  35 in total

Review 1.  Complement and the Kidney: An Overview.

Authors:  Joshua M Thurman
Journal:  Adv Chronic Kidney Dis       Date:  2020-03       Impact factor: 3.620

2.  Detection of Complement Factor B Autoantibodies by ELISA.

Authors:  Mihály Józsi; Barbara Uzonyi
Journal:  Methods Mol Biol       Date:  2021

Review 3.  Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Authors:  Marina Noris; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2018-06-09       Impact factor: 3.714

4.  Challenges in Understanding Acute Postinfectious Glomerulonephritis: Are Anti-Factor B Autoantibodies the Answer?

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2020-03-06       Impact factor: 10.121

5.  Anti-Factor B Antibodies and Acute Postinfectious GN in Children.

Authors:  Sophie Chauvet; Romain Berthaud; Magali Devriese; Morgane Mignotet; Paula Vieira Martins; Tania Robe-Rybkine; Maria A Miteva; Aram Gyulkhandanyan; Amélie Ryckewaert; Ferielle Louillet; Elodie Merieau; Guillaume Mestrallet; Caroline Rousset-Rouvière; Eric Thervet; Julien Hogan; Tim Ulinski; Bruno O Villoutreix; Lubka Roumenina; Olivia Boyer; Véronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2020-02-07       Impact factor: 10.121

6.  Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.

Authors:  Paraskevas Iatropoulos; Erica Daina; Manuela Curreri; Rossella Piras; Elisabetta Valoti; Caterina Mele; Elena Bresin; Sara Gamba; Marta Alberti; Matteo Breno; Annalisa Perna; Serena Bettoni; Ettore Sabadini; Luisa Murer; Marina Vivarelli; Marina Noris; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2017-10-13       Impact factor: 10.121

Review 7.  C3 glomerulopathy - understanding a rare complement-driven renal disease.

Authors:  Richard J H Smith; Gerald B Appel; Anna M Blom; H Terence Cook; Vivette D D'Agati; Fadi Fakhouri; Véronique Fremeaux-Bacchi; Mihály Józsi; David Kavanagh; John D Lambris; Marina Noris; Matthew C Pickering; Giuseppe Remuzzi; Santiago Rodriguez de Córdoba; Sanjeev Sethi; Johan Van der Vlag; Peter F Zipfel; Carla M Nester
Journal:  Nat Rev Nephrol       Date:  2019-03       Impact factor: 28.314

Review 8.  The role of the alternative pathway of complement activation in glomerular diseases.

Authors:  Emilia Łukawska; Magdalena Polcyn-Adamczak; Zofia I Niemir
Journal:  Clin Exp Med       Date:  2018-02-15       Impact factor: 3.984

9.  Clinical and functional consequences of anti-properdin autoantibodies in patients with lupus nephritis.

Authors:  M Radanova; G Mihaylova; D Ivanova; M Daugan; V Lazarov; L Roumenina; V Vasilev
Journal:  Clin Exp Immunol       Date:  2020-05-07       Impact factor: 4.330

Review 10.  The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease.

Authors:  Federica Defendi; Nicole M Thielens; Giovanna Clavarino; Jean-Yves Cesbron; Chantal Dumestre-Pérard
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.